Clinical trials and "real-world" medicine: Trial evidence best informs real-world medicine when it is relevant to the clinical problem

Medical Journal of Australia

Volumn 177, Issue 8, 2002, Pages 410-411

  Simes, R John ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; VITAMIN;

ARTHROSCOPIC SURGERY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; EDITORIAL; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; GOOD CLINICAL PRACTICE; HEALTH CARE COST; HISTORY OF MEDICINE; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KNEE OSTEOARTHRITIS; LUNG CANCER; MEDICAL DECISION MAKING; PATIENT ATTITUDE; QUALITY OF LIFE; RELIABILITY; RISK BENEFIT ANALYSIS; SIDE EFFECT; VITAMIN SUPPLEMENTATION;

EVIDENCE-BASED MEDICINE; HUMANS; PATIENT PARTICIPATION; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS;

EID: 0037152932     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (15)

1. Dans AL, Dans LF, Guyatt GH, Richardson S. Users' guides to the medical literature: XIV. How to decide on the applicability of trial results to your patient. JAMA 1998; 279: 545-549.
2. Simes RJ. Controlled clinical trials. In: Kerr C, Taylor R, Heard G, editors. Handbook of public health methods. Sydney: McGraw Hill, 1997: 130-136.
3. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
4. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145-1149.
5. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 23-33.
6. Moseley JB, O'Malley K, Petersen NJ, et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2002; 347: 81-88.
7. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity. II: Observational studies. Lancet 2001; 357: 455-462.
8. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357: 995-1001.
9. Kelly C, Ghazi F, Caldwell K. Psychological distress of cancer and clinical trial participation: A review of the literature. Eur J Cancer 2002; 11: 6-15.
10. Celemajer DS. Evidence-based medicine: How good is the evidence? Med J Aust 2001; 174: 293-295.
11. Australian Institute of Health and Welfare. Australia's health services expenditure to 1999-00. Health and Welfare Expenditure Series No. 6. Canberra: AIHW, 2001. (AIHW Cat. No. HWE-17.)
12. Detsky A. Using cost-effectiveness analysis to improve the efficiency of allocating funds to clinical trials. Stat Med 1990; 9: 173-184.
13. Glasziou PP. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. Med J Aust 1995; 162: 33-36.
14. Simes RJ, Glasziou PP. Meta-analysis and quality of evidence in the economic evaluation of drug trials. PharmacoEconomics 1992; 1: 282-292.
15. Horton R. Time to register randomised trials. Lancet 1999; 354: 1138-1139.